StemPro™ MSC SFM XenoFree
Invitrogen17万+抗体限时买二赠一,靶点广,灵活用!
StemPro™ MSC SFM XenoFree
Gibco™

StemPro™ MSC SFM XenoFree

GIBCO® StemPro® MSC SFM XenoFree 是一种无血清且无异种成分的完整培养基,适用于人间充质干细胞 (MSC) 和脂肪源性干细胞 (ADSC) 的生长和扩增了解更多信息
Have Questions?
货号数量
A10675011 个试剂盒
货号 A1067501
价格(CNY)
5,053.00
Each
添加至购物车
数量:
1 个试剂盒
价格(CNY)
5,053.00
Each
添加至购物车
GIBCO® StemPro® MSC SFM XenoFree 是一种无血清且无异种成分的完整培养基,适用于人间充质干细胞 (MSC) 和脂肪源性干细胞 (ADSC) 的生长和扩增。使用 StemPro® MSC SFM XenoFree 培养基,人 MSC 或 ADSC 可以多次传代扩增并保持其多向分化潜能表型(即,分化为成骨细胞、成软骨细胞和成脂肪细胞谱系的能力)。StemPro® MSC SFM XenoFree 培养基符合 cGMP 标准,具有可溯源性和生产可靠性。
仅供科研使用。不可用于诊断程序。
规格
细胞类型间充质干细胞
培养环境CO2
所含抗生素不含抗生素
产品线StemPro
产品类型干细胞无血清培养基 (SFM)
纯度或质量等级MS 细胞合格
数量1 个试剂盒
种属
分类无异种成分
培养类型贴壁细胞培养
形式液体
血清水平无血清
不加添加剂无谷氨酰胺, 无酚红
Unit SizeEach
内容与储存
每个试剂盒含有 1 x 500 mL StemPro™ MSC SFM 基础培养基和 1 x 5 mL StemPro™ MSC SFM XenoFree 补充剂。StemPro™ MSC SFM 基础培养基在 2 至 8°C 下储存,可保持稳定12个月。StemPro™ MSC SFM XenoFree 补充剂在 -5 至 -20°C 下冷冻储存,可保持稳定12个月。

常见问题解答 (FAQ)

What is the concentration of sodium bicarbonate in StemPro MSC SFM XenoFree?

StemPro MSC SFM XenoFree contains 2.2 g/L of sodium bicarbonate.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

引用和文献 (13)

引用和文献
Abstract
Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity.
Authors:Haraszti RA,Miller R,Stoppato M,Sere YY,Coles A,Didiot MC,Wollacott R,Sapp E,Dubuke ML,Li X,Shaffer SA,DiFiglia M,Wang Y,Aronin N,Khvorova A
Journal:Molecular therapy : the journal of the American Society of Gene Therapy
PubMed ID:30341012
Exosomes can deliver therapeutic RNAs to neurons. The composition and the safety profile of exosomes depend on the type of the exosome-producing cell. Mesenchymal stem cells are considered to be an attractive cell type for therapeutic exosome production. However, scalable methods to isolate and manufacture exosomes from mesenchymal stem cells ... More
Diverse impact of xeno-free conditions on biological and regenerative properties of hUC-MSCs and their extracellular vesicles.
Authors:Bobis-Wozowicz S,Kmiotek K,Kania K,Karnas E,Labedz-Maslowska A,Sekula M,Kedracka-Krok S,Kolcz J,Boruczkowski D,Madeja Z,Zuba-Surma EK
Journal:Journal of molecular medicine (Berlin, Germany)
PubMed ID:27638341
ABSTRACT: Growing evidence indicates that intracellular signaling mediated by extracellular vesicles (EVs) released by stem cells plays a considerable role in triggering the regenerative program upon transplantation. EVs from umbilical cord mesenchymal stem cells (UC-MSC-EVs) have been shown to enhance tissue repair in animal models. However, translating such results into ... More
Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions.
Authors:Santos Fd,Andrade PZ,Abecasis MM,Gimble JM,Chase LG,Campbell AM,Boucher S,Vemuri MC,Silva CL,Cabral JM
Journal:Tissue engineering. Part C, Methods
PubMed ID:21895491
The immunomodulatory properties of mesenchymal stem cells (MSCs) make them attractive therapeutic agents for a wide range of diseases. However, the highly demanding cell doses used in MSC clinical trials (up to millions of cells/kg patient) currently require labor intensive methods and incur high reagent costs. Moreover, the use of ... More
A xeno-free microcarrier-based stirred culture system for the scalable expansion of human mesenchymal stem/stromal cells isolated from bone marrow and adipose tissue.
Authors:Carmelo JG, Fernandes-Platzgummer AM, Diogo MM, Lobato da Silva C, Cabral JM,
Journal:
PubMed ID:26136376
'Human mesenchymal stem/stromal cells (MSC) are promising candidates for cell-based therapies and the development of microcarrier-based cultures in scalable bioreactors with well-defined xenogeneic-free components represent important milestones towards the clinical-scale production of these cells. In this work, we optimized our previously developed xeno-free microcarrier-based system for the scalable expansion of ... More
Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media.
Authors:Oikonomopoulos A, van Deen WK, Manansala AR, Lacey PN, Tomakili TA, Ziman A, Hommes DW,
Journal:
PubMed ID:26564250
'Due to their immunosuppressive properties, mesenchymal stem cells (MSC) have been evaluated for the treatment of immunological diseases. However, the animal-derived growth supplements utilized for MSC manufacturing may lead to clinical complications. Characterization of alternative media formulations is imperative for MSC therapeutic application. Human BMMSC and AdMSC were expanded in ... More